Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

Crohn’s disease: A race for market leadership AbbVie’s Skyrizi holds the distinction of being the first anti-IL-23p19 therapy approved for Crohn’s disease (CD) in 2022 across the US and EU.

The ACG has released new clinical guidelines for the management of ulcerative colitis and Crohn’s disease in adult patients.The guidelines, published in The American Journal of Gastroenterology ...

According to Berenberg’s analysis, last year Novo Nordisk and Eli Lilly generated a RORI of 26 per cent and 24 per cent, respectively, with AstraZeneca coming in a respectable third with 14 per cent.

Cedars-Sinai investigators have developed an investigational therapy that brought a significant number of patients with ...

Bhat: From a medication standpoint, there is still much to uncover regarding why treatments vary in effectiveness among ...

In a European study, higher consumption of fruits, vegetables, legumes, and potatoes was associated with a reduced risk of ...

Up to half of patients with Crohn's disease, an inflammatory bowel disease, develop a complication called fibrosis, where the ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

Crohn's disease. Read the latest research on Crohn's disease: risk factors, reducing flare ups, and new treatment options. Skip to main content. Your source for the latest research news.

Crohn’s disease and celiac disease are both gastrointestinal (GI) conditions that can cause abdominal pain, diarrhea, and other symptoms. While both diseases cause inflammation in the GI tract ...

Crohn's disease is a chronic inflammatory bowel disease (IBD) that affects the digestive tract, often causing abdominal pain, persistent diarrhea, rectal bleeding, weight loss, and fatigue during ...